| ²é¿´: 2591 | »Ø¸´: 36 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
ccxyx1124½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
CGMPÅàѵ×ÊÁÏ-Õã½Ò©¼à¾Ö&ÃÀ¹úÖÞ¼ÊÒ©ÒµºÍCGMPÖÐÎİ桢Agilent1100ÖÐÎŤ×÷Õ¾
|
||
|
2006ÄêÈýÔÂÕã½Ò©¼à¾Ö&ÃÀ¹úÖÞ¼ÊÒ©ÒµÁªºÏµÄCGMPÅàѵ×ÊÁÏ£¬ÏëѧϰµÄ¿´¿´°¡£¡ ÓÖÔö¼ÓÁËCGMPÖÐÎİ棡 ÀïÃæ»¹ÓÐAgilent1100ÖÐÎŤ×÷Õ¾ ccxyx1124@56.com Ç°Ãæ²»ÄÜÏÂÔØµÄÒÑ·¢Ë͵½ÓÊÏ䣬Çë²éÊÕ£¡ [ Last edited by ccxyx1124 on 2006-5-17 at 12:31 ] |
» ²ÂÄãϲ»¶
312Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
»¯Ñ§¹¤³Ì321·ÖÇóµ÷¼Á
ÒѾÓÐ16È˻ظ´
280Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
¹¤¿Æ²ÄÁÏ085601 279Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
»·¾³¹¤³Ìµ÷¼Á
ÒѾÓÐ8È˻ظ´
302Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
½¹ÂÇ
ÒѾÓÐ10È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
½ðÊôÊÖ²áÖÐÎİ棨ÌúÓë¸Ö£¬¼Ó¹¤¹¤ÒÕ£©
ÒѾÓÐ57È˻ظ´
ÃÀ¹úÒ©Æ··ÖÎöʵÑéÊÒCGMPµÄʵʩºÍ²Ù×÷.ppt
ÒѾÓÐ95È˻ظ´
ͨ¹ýÅ·ÃËCGMPµÄÆóÒµÃûµ¥
ÒѾÓÐ26È˻ظ´
¹úÄÚÖÆÒ©ÆóÒµ·µ¹¤ºÍβÁÏ»ØÊÕÇé¿öµÄµ÷Ñм°Ì½ÌÖ£¨ÉϺ£Ò©¼à¾Öò§ËïÑà¡¢Áõΰǿ¡¢ÕÅ»ªµÈ£©
ÒѾÓÐ39È˻ظ´
Guidance for Industry CGMP for Phase 1 Investtgational Drugs
ÒѾÓÐ2È˻ظ´
ÈõÈõµÄÎÊ£ºcGMP¸úGMPµÄ²î„e??
ÒѾÓÐ9È˻ظ´
FDA¹¤ÒµÖ¸ÄÏ--CGMPµÄÖÊÁ¿Ìåϵ(ÖÐÓ¢ÎÄ£©
ÒѾÓÐ193È˻ظ´
ÄϾ©ÏÈÉùÒ©Òµ
ÒѾÓÐ37È˻ظ´
Ñï×Ó½Ò©ÒµËÄ´¨º£ÈØÒ©ÒµÇé¿öÔõôÑùÄØ£¿
ÒѾÓÐ20È˻ظ´
¡¾×ªÌû¡¿"µ¹Âô"ÐÂÒ©¼¼Êõ×ÊÁÏ Ò©¼à¾Ö¹ÙÔ±ÊÜ»ß130ÍòÅÐ11Äê
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿GMPºÍcGMPµÄ¾ßÌåÇø±ð£¿
ÒѾÓÐ45È˻ظ´

pharm
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 14300.7
- Ìû×Ó: 564
- ÔÚÏß: 77.6Сʱ
- ³æºÅ: 42934
- ×¢²á: 2004-04-03
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
5Â¥2006-04-18 03:41:54
2Â¥2006-04-17 12:54:32
ccxyx1124
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1677.5
- Ìû×Ó: 190
- ÔÚÏß: 5.6Сʱ
- ³æºÅ: 75312
- ×¢²á: 2005-06-17
- ÐÔ±ð: GG

7Â¥2006-04-18 10:34:59
huigenghao
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 15 (СѧÉú)
- ¹ó±ö: 0.126
- ½ð±Ò: 22056
- É¢½ð: 56
- ºì»¨: 13
- Ìû×Ó: 1681
- ÔÚÏß: 241.4Сʱ
- ³æºÅ: 29283
- ×¢²á: 2003-11-23
- ÐÔ±ð: GG
- רҵ: ֪ʶ¹ÜÀí
8Â¥2006-04-18 18:46:10













»Ø¸´´ËÂ¥
